Stay updated with breaking news from B Pfizer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Pfizer pill for COVID-19 reduced the risk of hospitalization or death by 89% compared to a placebo group, the company said Tuesday in final study results that are similar to initial findings. Pfizer also said its drug, Paxlovid, showed "robust antiviral activity" against the omicron variant in lab studies.
A two-dose Pfizer/BioNTech vaccination provides just 33% protection against infection by the omicron variant of the coronavirus, but 70% protection against hospitalization, according to a large-scale analysis in South Africa released Tuesday.
A Pfizer pill for COVID-19 reduced the risk of hospitalization or death by 89% compared to a placebo group, the company said Tuesday in final study results that are similar to initial findings. Pfizer also said its drug, Paxlovid, showed "robust antiviral activity" against the omicron variant in lab studies.
The U.S. is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer's vaccine.
The U.S. is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer's vaccine.